Transaction #4899 · Form 4 · 0001884123-25-000010
Marker Therapeutics, Inc. · Stock award · Stock Option (Right to Buy)
Marker Therapeutics, Inc. · Transacted October 31, 2025 · Filed November 4, 2025
What does this filing report?
An SEC Form 4 filing for Marker Therapeutics, Inc. records a stock award involving Stock Option (Right to Buy) on October 31, 2025. The reported quantity was 147,611. The filing date is November 4, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Marker Therapeutics, Inc.
- Company CIK
- 0001094038
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 147,611
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 147,611
- Ownership description
- Not reported
- SEC acceptance time
- Nov 4, 2025, 5:09 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Corzo Kathryn Penkus ↗
Director
CIK 0001884123
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 147,611
- Conversion / exercise price
- 0.9877
- Exercise date
- Not reported
- Expiration date
- October 31, 2035
Filing footnotes & remarks
- F1
- Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. The shares vest equally over thirty six (36) monthly installments, subject to the Reporting Person's continued service as a director. The option exercise price is the closing price on the date of the grant, October 31, 2025.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.